GlobalData offers a comprehensive analysis of WuXi Biologics Cayman, providing key insights into its Environmental, Social, and Governance(ESG) factors. By closely monitoring and aggregating mentions of Net Zero and associated ESG keywords, GlobalData delivers valuable information on WuXi Biologics Cayman‘s ESG performance. GlobalData’s company profile on WuXi Biologics Cayman offers a 360-degree view of the company, SWOT analysis, key financials, and business strategy including insights on ESG implementation among other information. Buy the report here.

WuXi Biologics Cayman, a global open-access biologics technology platform company, has set target achieve net-zero emissions from overall operations by 2050. The company’s latest filings mentioned the keywords 'Climate Change' and 'Emissions' most number of times in relation to ‘Net-Zero’.

WuXi Biologics Cayman has identified scope 1, scope 2, and scope 3 emissions as specific goals to reduce its carbon footprint. In 2022, the company reported Greenhouse gas Scope 1 Emissions at 33,762 tCO2e and Greenhouse gas Scope 2 Emissions at 136,067 tCO2e. The breakdown of company’s Scope 3 emissions is as follows - Upstream transportation and distribution: 2,431.75 tCO2e, Waste generated in operations: 2,944.18 tCO2e, Employee commuting: 20,400 tCO2e, and Downstream transportation and distribution: 1,169.96 tCO2e.

WuXi Biologics Cayman has taken steps to reduce its carbon emissions and has joined the RE100 global corporate renewable energy initiative. The company has calculated the electricity emission factor based on the average carbon dioxide emission factor of China's provincial power grids in 2010. The natural gas emission factor is calculated based on GB/T 2589-2020 and IPCC 2006. The company has also disclosed its direct emissions and indirect GHG emissions from purchased electricity and steam.

In 2022, WuXi Biologics Cayman achieved a reduction of 21% GHG emissions intensity (scope1 and scope2) compared with 2021, which exceeded its annual target and contributed significantly toward achieving the net-zero goal. The company's mid-term goal is to reduce Scope 1 and 2 greenhouse gas (GHG) emissions intensity by 50% by 2030 from the baseline year 2020 (tonnes/RMB10,000). WuXi Biologics Cayman has implemented Water Excellence Stewardship (WES), an internal water management plan at site-specific to manage water quality. The company has also complied with various laws and regulations, including the Environmental Protection Law of the People's Republic of China, the Law of the People's Republic of China on Energy Conservation, and the Cleaner Production Promotion Law of the People's Republic of China.

In conclusion, WuXi Biologics Cayman has set a net-zero target to reduce its carbon emissions by 2050. The company has taken steps to reduce its carbon emissions, achieved significant progress in reducing its emissions and has set mid-term targets to reach the end goal of achieving net-zero targets. WuXi Biologics Cayman has also complied with various laws and regulations related to environmental protection and energy conservation.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies representing the world’s largest industries. This analysis is combined with crucial details on strategic and investment priorities, innovation strategies, and CXO insights to provide comprehensive company profiles.